A study that reveals the most accurate blood tests to diagnose the atrophic side cllerosis

In a recent study, the best blood tests were found that help diagnose and monitor its development, which affects the nervous system, leading to the gradual decline of motor neurons. The atrophic lateral sclerosis is one of the most difficult to diagnose or predict in its early stages quickly, and doctors emphasize the importance of providing accurate important indicators to diagnosing the disease and detecting their different phases, which can contribute to improving the treatment strategies and providing better care for patients. The researchers said that the presence of an effective vital indication not only helps with the diagnosis, but that it can be a decisive tool to expect the development of the disease, to determine the stage that the patient has reached, and to judge his response to treatments. The study, published in the Journal of the American Academy of Neurosciences, compared three types of biomedics in the blood to determine the extent of their accuracy in the diagnosis of atrophic lateral sclerosis, as it contains the protein responsible for transferring signals in neurons known as norophilin chains, which prevents or the sour protein is, which prevents neurons, and the process of restoring neurons, which is neurons, neurons, neurons is the tau protein associated with the accumulation of substances that cause brain disorders such as Alzheimer’s. The researchers also tested several ways to measure the first protein levels to find out the most accurate and effective diagnosis. 139 People with atrophic lateral sclerosis participated in the study, in addition to 70 people suffering from similar neurological diseases, such as lower motor neuron and first silk sclerosis. On average, the researchers continued the participants about 3 and a half years for people with everything, and on average, for people who were not infected with the disease, and during this period 86% of those with atrophic side cllerosis died, compared to only 8% of those with other diseases. Promising results, and the results showed that the levels of mild norophilin protein in the blood of the atrophic lateral sclerosis patients were three times higher compared to people with other diseases. This test was also the most accurate as it managed to diagnose the disease by more than 80%, compared to a relatively low accuracy of the acid protein and the tau phosphorus protein, which amounts to only 50%. The researchers were able to determine a certain level of light norophylin protein, can help predict survival in patients with atrophic lateral sclerosis. Within one year, more than 40% of people with lower levels of this degree were still alive, while no patient survived this limit. Despite the need for more studies to confirm these results, determining the protein level as a factor for expecting the disease can be useful for patients and their families, as well as for doctors who treat them. The researchers pointed out that obtaining more accurate information on the diagnosis and path of the disease can help improve treatment strategies and make decisions based on more accurate evidence. The study faced a number of challenges; The generalization of the results of this study is that all the participants from one region were in France, which could affect the possibility of applying the results on a broader scale that includes patients of different geographical and ethnic backgrounds.